Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 or over diagnosed with rheumatoid arthritis after the age of 16~* Active rheumatoid arthritis defined as: ≥4 swollen joints and ≥4 tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate ≥28 mm/h, or C-reactive protein ≥10 mg/L.~* Currently taking one of the following disease-modifying anti-rheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine.~* Patients without essential hypertension or with essential hypertension if their blood pressure is controlled (\<140/90 mmHg) with anti-hypertensive medications being stable at least 4 weeks prior to randomisation.~Exclusion Criteria:~* Females who are pregnant or breastfeeding.~* Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders~* History of liver problems that have required previous investigations~* Evidence of tuberculosis infection~* Conditions that preclude or render difficult the 24-hour ambulatory blood pressure monitoring technique.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing Regimen A (Type: EXPERIMENTAL): Oral treatment
- Dosing Regimen B (Type: PLACEBO_COMPARATOR): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).